E-Mail
ROCKVILLE, Md. - June 10, 2021 - The Association for Molecular Pathology (AMP), the premier global, molecular diagnostic professional society, today published consensus recommendations to aid in the design and validation of clinical CYP2D6 assays, promote standardization of testing across different laboratories and improve patient care. The manuscript, Recommendations for Clinical CYP2D6 Genotyping Allele Selection: A Joint Consensus Recommendation of the Association for Molecular Pathology, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, and European Society for Pharmacogenomics and Personalized Therapy, was released online ahead of publication in The
Journal of Molecular Diagnostics.
Share this article
Share this article
BETHESDA, Md., May 20, 2021 /PRNewswire/ The American College of Medical Genetics and Genomics (ACMG) has just released an updated policy statement and gene list for the reporting of secondary findings (SF). Together, these two documents update the recommendations for SF reporting and unveil the highly anticipated recommended minimum gene list
(SF v3.0) for reporting secondary findings in clinical exome and genome sequencing. The ACMG also declares its intent to update the SF gene list now annually, with a goal of publishing the updated list each January.
Genetics in Medicine. Our group worked very hard on this update, taking a thoughtful and careful approach that balances the goals of keeping it as a minimum list while also providing results that will impact patients and their families in a positive way, said lead author and co-chair of the ACMG SFWG, David T. Miller, MD, PhD, FACMG.
Children s Tumor Foundation
The Children’s Tumor Foundation (CTF) today announced the publication of updated diagnostic criteria for the genetic disorder neurofibromatosis type 1 (NF1) in Genetics in Medicine, the official journal of the American College of Medical Genetics and Genomics. The new publication is the result of an extensive, multi-year collaborative effort of over 90 leading neurofibromatosis (NF) experts from around the globe, and is aimed at improving the accuracy and earlier diagnosis of NF1 in patients, thus ultimately leading to improved care and quality of life for those patients. Today’s announcement is being made on the occasion of NF Awareness Month, a global awareness initiative focused on increasing recognition of all the forms of neurofibromatosis and schwannomatosis.
Children s Tumor Foundation announces revised diagnostic criteria for NF1 eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
Children s Tumor Foundation Announces Revised Diagnostic Criteria for Neurofibromatosis Type 1 (NF1), Affecting over 2 5 Million People Worldwide prweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prweb.com Daily Mail and Mail on Sunday newspapers.